Entrada Therapeutics, Inc. (TRDA) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TRDA Revenue Growth
Revenue Breakdown (FY 2025)
TRDA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
TRDA Revenue Analysis (2019–2025)
As of May 8, 2026, Entrada Therapeutics, Inc. (TRDA) generated trailing twelve-month (TTM) revenue of $5.7 million, reflecting significant decline in growth of -95.7% year-over-year. The most recent quarter (Q1 2026) recorded $875,000 in revenue, down 32.6% sequentially.
Looking at the longer-term picture, TRDA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $210.8 million in 2024.
Revenue diversification analysis shows TRDA's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARWR (+14.1% YoY), NTLA (+16.9% YoY), and BEAM (+108.0% YoY), TRDA has underperformed the peer group in terms of revenue growth. Compare TRDA vs ARWR →
TRDA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TRDACurrent | $6M | -95.7% | - | -613.7% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
TRDA Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $25.4M | -87.9% | $21.3M | 83.9% | $-155,998,000 | -613.7% |
| 2024 | $210.8M | +63.4% | $210.8M | 100.0% | $47.0M | 22.3% |
| 2023 | $129.0M | - | $129.0M | 100.0% | $-3,162,000 | -2.5% |
| 2022 | $0 | - | $0 | - | $-97,248,000 | - |
| 2021 | $0 | - | $0 | - | $-51,127,000 | - |
| 2020 | $0 | - | $-326,000 | - | $-26,667,000 | - |
| 2019 | $0 | - | $-104,000 | - | $-11,824,000 | - |
See TRDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTRDA — Frequently Asked Questions
Quick answers to the most common questions about buying TRDA stock.
Is TRDA's revenue growth accelerating or slowing?
TRDA revenue declined -95.7% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $6M. This reverses the prior growth trend.
What is TRDA's long-term revenue growth rate?
Entrada Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -95.7% is below this long-term average.
How is TRDA's revenue distributed by segment?
TRDA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.